title: Efficacy and safety of antiviral therapy in patients with Crohn's disease and chronic hepatitis C.
abstract: BACKGROUND
  Efficacy and safety of antiviral combination therapy in patients with Crohn's disease (CD) and chronic hepatitis C (CHC) is presently not established and consequently CHC is rarely treated in CD patients.
  
  
  OBJECTIVE
  To analyse the efficacy and tolerability of antiviral interferon/ribavirin therapy in patients with CHC and CD.
  
  
  METHODS
  Eleven HCV-infected CD patients received either 3 x 1.5 microg/kg/week interferon-alpha-2b or 180 microg/week peginterferon-alpha-2a (PEGASYS; Roche, Basel, Switzerland) as monotherapy (n = 1) or in combination with 800-1200 mg/day ribavirin (COPEGUS; Roche) (n = 10) for 24-54 weeks according to HCV-genotype and initial response respectively. Eight patients were under CD-specific therapy.
  
  
  RESULTS
  Five (46%) patients (HCV-1: a = 3; HCV-2: n = 0; HCV-3: n = 1; unknown: n = 1) achieved a sustained virological response, three (27%) patients relapsed, three (27%) were nonresponders (all GT 1b). At baseline, the Harvey--Bradshaw Index was 0 (0-8) [median (range)], increased on antiviral therapy to 4 (1-15) (P = 0.005) and decreased to baseline level 0 (0-6) after 6-month follow-up.
  
  
  CONCLUSIONS
  This preliminary experience demonstrates that treatment of CHC in patients with CD is comparable to the treatment of CHC in those without CD. However, gastrointestinal symptoms may be temporarily exacerbated and haemopoietic growth factors may be required.
authors.affiliation: Internal Medicine III, Department of Gastroenterology and Hepatology, Medical University of Vienna, Vienna, Austria. thomas-matthias.scherzer@meduniwien.ac.at
authors.forename: T M
authors.initials: TM
authors.lastname: Scherzer
authors.forename: K
authors.initials: K
authors.lastname: Staufer
authors.forename: G
authors.initials: G
authors.lastname: Novacek
authors.forename: P
authors.initials: P
authors.lastname: Steindl-Munda
authors.forename: S
authors.initials: S
authors.lastname: Schumacher
authors.forename: H
authors.initials: H
authors.lastname: Hofer
authors.forename: P
authors.initials: P
authors.lastname: Ferenci
authors.forename: H
authors.initials: H
authors.lastname: Vogelsang
mesh_terms: D000328:Adult; D000998:Antiviral Agents / Q000627:therapeutic use*; D015897:Comorbidity; D003424:Crohn Disease / Q000188:drug therapy* / Q000453:epidemiology / Q000276:immunology; D004359:Drug Therapy, Combination; D005260:Female; D016174:Hepacivirus / Q000302:isolation & purification; D019698:Hepatitis C, Chronic / Q000188:drug therapy* / Q000453:epidemiology / Q000276:immunology; D006801:Humans; D016867:Immunocompromised Host / Q000276:immunology*; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use*; D007958:Leukocyte Count; D008297:Male; D008875:Middle Aged; D011092:Polyethylene Glycols / Q000627:therapeutic use*; D016133:Polymerase Chain Reaction; D012367:RNA, Viral / Q000097:blood; D011994:Recombinant Proteins; D012189:Retrospective Studies; D012254:Ribavirin / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D000998:Antiviral Agents; D007166:Immunosuppressive Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D012367:RNA, Viral; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; C100416:peginterferon alfa-2a